Delisting riskPopularity #4,794
Calidi Biotherapeutics (CLDI)
Develops systemic oncolytic-virus platforms that deliver therapeutic payloads into tumors.
$1.09
vs last close−0.02 (−1.80%)
Something off on this page? Send us feedback.
Next report
Nov 17, 26
estimated · in 55 days
EPS estimate
—
Revenue estimate
—
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Apr '25May '25Aug '25Nov '25Mar '26Mar '26Aug '26Nov '26
Reported−$51.84−$34.56−$31.84−$35.36−$9.12−$6.88−$2.94Pending
Estimate−$71.04−$28.80−$30.72−$26.88−$24.96———
Surprise+27.0%−20.0%−3.6%−31.5%+63.5%———
RevenueReportedEstimate
Apr '25May '25Aug '25Nov '25Mar '26Mar '26Aug '26Nov '26
Reported———————Pending
Estimate————————
Surprise————————
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | — | — | — |
| Aug 2026 | — | −$2.94 | — |
| Mar 2026 | — | −$6.88 | — |
| Mar 2026 | −$24.96 | −$9.12 | +63.5% |
| Nov 2025 | −$26.88 | −$35.36 | −31.5% |
| Aug 2025 | |||
| May 2025 | |||
| Apr 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Nov 17, 2026 | — | — | — | — | — | — | — |
| Aug 13, 2026 | — | −$2.94 | — | — | — | — | +3.3% |
| Mar 30, 2026 | — | −$6.88 | — | — | — | — | −11.6% |
| Mar 27, 2026 | −$24.96 | −$9.12 | +63.5% | — | — | — | −3.8% |
| Nov 11, 2025 | −$26.88 | −$35.36 | −31.5% | — | — | — | +4.3% |
| Aug 12, 2025 | |||||||
| May 13, 2025 | |||||||
| Apr 4, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 13, 2024 | |||||||
| May 14, 2024 | |||||||
| Mar 15, 2024 | |||||||
| Nov 14, 2023 | |||||||
| Aug 21, 2023 |